Activated PI3K delta syndrome

Disease ID:1199
Name:Activated PI3K delta syndrome
Associated with:1 targets
1 immuno-relevant targets
3 immuno-relevant ligands
Synonyms
APDS/PASLI | Immunodeficiency 14 | p110 delta activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency
Description
A rare autosomal dominant, genetic disease causing primary immunodeficiency and characterised by lymphadenopathy, immunodeficiency leading to recurrent infections, and an increased risk of EBV-associated lymphoma.
Database Links
OMIM: 615513
Orphanet: ORPHA397596

Targets

phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
Comments:  The effects of constitutive PI3Kδ activation in this syndrome are the opposite (or inverse) of the effects mediated by pharmacological PI3Kδ inhibition.
Mutations:  phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta is associated with 1 mutation. Click here for details
Ligand interactions
Ligand Name Disease Association Comments Approved Primary Target Immuno
nemiralisib
Phase 2 clinical candidate for this condition (see NCT02593539).
leniolisib
Phase 1 clinical lead for APDS. Early clinical trial (NCT02435173) results are published. Lymphoproliferation and immune dysregulation are ameliorated ...

Ligands

Ligand Approved Immuno References Clinical comments
nemiralisib
Clinical Use: Nemiralisib (as GSK2269557) is in Phase 2 clinical development. Two separate studies are underway in patients with chronic obstructive pulmonary disease (COPD; NCT02522299) or the rare genetic condition activated PI3K-delta syndrome (APDS/PASLI; NCT02593539).
Immuno Disease Comments: Phase 2 clinical candidate for this condition (see NCT02593539).
leniolisib 4
Clinical Use: Being evaluated in clinical trial in patients with genetically activated PI3Kδ (i.e. patients with APDS/PASLI; see Phase 2/3 trial NCT02435173). Positive results from NCT02435173 are reported by Rao et al. (2017) [4], showing that leniolisib was well tolerated and improved laboratory and clinical parameters in APDS patients.
Immuno Disease Comments: Phase 1 clinical lead for APDS. Early clinical trial (NCT02435173) results are published. Lymphoproliferation and immune dysregulation are ameliorated in APDS patients following 12 weeks of leniolisib treatment.
sirolimus  [  (Drugs.com) ]
Clinical Use: Sirolimus is used for prophylaxis of renal transplant rejection [1,5], and may be used in combination with . In June 2015 the US FDA approved sirolimus for the treatment of lymphangioleiomyomatosis, a rare proliferative but benign lung disease [3].
Immuno Disease Comments: Phase 1/2 clinical candidate for APDS (NCT03383380).

References

Show »

1. Kelly PA, Gruber SA, Behbod F, Kahan BD. (1997) Sirolimus, a new, potent immunosuppressive agent. Pharmacotherapy, 17 (6): 1148-56. [PMID:9399599]

2. Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, Avery DT, Moens L, Cannons JL, Biancalana M et al.. (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol., 15 (1): 88-97. [PMID:24165795]

3. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM et al.. (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N. Engl. J. Med., 364 (17): 1595-606. [PMID:21410393]

4. Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M et al.. (2017) Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood, 130 (21): 2307-2316. [PMID:28972011]

5. Vasquez EM. (2000) Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm, 57 (5): 437-48; quiz 449-51. [PMID:10711524]